TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00522041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
Study: NCT00212433
Drug: Tagitol V, Lo So, Readi-Cat 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00620542
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsule, oral, once daily
Study: NCT01282268
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally disintegrating tablet
Study: NCT03723759
Drug: Faster Aspart 200 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
Study: NCT03723759
Drug: Faster aspart 100 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
Study: NCT00288704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
Study: NCT03224572
Drug: high-dose vitamin C 30gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
Study: NCT02385760
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02385760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00678145
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study: NCT03388463
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg single daily dose.
Study: NCT00544167
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00544167
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02597257
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline continuous infusion
Study: NCT03410030
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combination therapy
Study: NCT01903057
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01903057
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00624455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00620919
Drug: RG1068 (Synthetic Human Secretin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT04499209
Drug: Combination of Naproxen and Pregabalin
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
Study: NCT01437735
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 po
Study: NCT01437735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03008005
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
Study: NCT03358147
Drug: GP MDI 28.8 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
Study: NCT03358147
Drug: GP MDI 14.4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
Study: NCT03358147
Drug: GP MDI 7.2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
Study: NCT03358147
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken as 2 inhalations BID
Study: NCT03358147
Drug: Spiriva Respimat 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva Respimat 2.5 μg QD (open-label)
Study: NCT01756716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 8 weeks
Study: NCT02694653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
Study: NCT02694653
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
Study: NCT03575351
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT00646984
Drug: Standard continuous antiretroviral therapy
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00646984
Drug: CD-4 guided therapy interruption
Normalized name: Zostrix Cold Therapy 4 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
Study: NCT00646984
Drug: Viral load driven treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
Study: NCT04535986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
Study: NCT00630253
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
Study: NCT01328782
Drug: Oxycodone with Acetaminophen
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
Study: NCT03312894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets
Study: NCT01129479
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill each morning with food for 12 weeks.
Study: NCT00314093
Drug: RFT5pdgA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02556814
Drug: Caffeic acid tablets
Normalized name: caffeic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
Study: NCT02556814
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo tablets 0.3g three times per day for 3 months
Study: NCT00070122
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00070122
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00070122
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01257451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 50mg bid
Study: NCT02637180
Drug: anti-osteoporotic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: check previous information
Study: NCT00476034
Drug: lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01799850
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo assigned randomly, double blind
Study: NCT04229394
Drug: 2ccPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1
Study: NCT04229394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1
Study: NCT01046084
Drug: Prevacid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Delayed-Release Capsule
Study: NCT00958152
Drug: VCH-222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
Study: NCT00958152
Drug: VCH-222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
Study: NCT00958152
Drug: VCH-222
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
Study: NCT04009941
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5mg per cycle, 24 hours after chemotherapy
Study: NCT03247530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered once daily
Study: NCT03247530
Drug: 100mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg SPN-812 was administered once daily and compared to placebo
Study: NCT00929006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Study: NCT00459407
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03247530
Drug: 200mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study: NCT02256930
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03732833
Drug: MT10109L
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109L will be injected into either the LCL, or both the LCL and GL.
Study: NCT03732833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Study: NCT02256930
Drug: M518101 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04997551
Drug: Colchcine
Normalized name: COLCHCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day
Study: NCT00000534
Drug: calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00694291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT04320745
Drug: Androderm®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androderm® transdermal dose.
Study: NCT02605642
Drug: CT-P13
Approvals — FDA: no, EMA: no, PMDA: no
Description: biosimilar infliximab
Study: NCT02601924
Drug: 20% Benzocain (Master-Dent, Monroe, NC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
Study: NCT00546637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02533427
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet administered orally once daily
Study: NCT00096460
Drug: Non-myeloablative Conditioning regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
Study: NCT02533427
Drug: Norgestimate/ethinyl estradiol
Normalized name: Norgestimate/Ethinyl Estradiol 28-Day 0.215mg-0.025mg/0.25mg-0.025mg/0.18mg-0.025mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
Study: NCT00022139
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01390909
Drug: Anti-epileptic drug (AED)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
Study: NCT05324891
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
Study: NCT00855660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a single tablet, thrice daily, over 14 days.
Study: NCT01577173
Drug: MEHD7945A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 mg iv every 2 weeks
Study: NCT00568555
Drug: Placebo - sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill once daily
Study: NCT03792139
Drug: LY3200882
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00046839
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00662896
Drug: naproxen 250 mg bid
Normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 250 mg bid
Study: NCT00662896
Drug: naproxen 500 mg bid
Normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen 500 mg bid
Study: NCT00662896
Drug: ibuprofen 600 mg tid
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 600 mg tid
Study: NCT01887795
Drug: WBRT
Normalized name: Whole Brain Radiation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03548155
Drug: atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any atypical antipsychotic drug as the basic treatment
Study: NCT03548155
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
Study: NCT01650155
Drug: BI 1005273 s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT01650155
Drug: BI 105273 i.v. Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT01650155
Drug: BI 1005273 s.c. Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT01650155
Drug: BI 1005273 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT03864458
Drug: KHK7791
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03864458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02582307
Drug: Acetaminophen, Analgesics, Non-Narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT02582307
Drug: Hyoscine butylbromide, Analgesics, Non-Narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT01006954
Drug: Flare up
Normalized name: OATMEAL 1 g in 100 g TOPICAL CREAM [Eucerin Eczema Relief Flare Up Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flare up protocol in poor responders for IVF/ICSI
Study: NCT02011451
Drug: 95% Pure ECGC capsules 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theaphenon 95% 95% Pure EGCG
Study: NCT02011451
Drug: Placebo Comparator:
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03350191
Drug: SAR425899
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT03350191
Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT01277510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets and capsules for sprinkling identical to active treatment.
Study: NCT01277510
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
Study: NCT01291173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken once daily for up to 11 weeks
Study: NCT02118792
Drug: AN2728 Topical Ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02118792
Drug: Matching vehicle control
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00485888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to Cipralex
Study: NCT00653250
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
Study: NCT01611506
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Study: NCT02013050
Drug: SGX942
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02013050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03825198
Drug: NaCL 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Study: NCT03825198
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Study: NCT01266954
Drug: GSK2141795
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
Study: NCT03629067
Drug: Treatment T
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
Study: NCT02461563
Drug: 200 mg MK-1075
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study: NCT03825198
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
Study: NCT02461563
Drug: 400 mg MK-1075
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study: NCT02737462
Drug: CG200745 PPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
Study: NCT02835157
Drug: Balanced crystalloid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple electrolyte solution as boluses would be administered.
Study: NCT02461563
Drug: 800 mg MK-1075
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Study: NCT00003479
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT04123587
Drug: discontinuation of Sulfonylureas
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent
Study: NCT00748787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
Study: NCT02597049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC